ASH 2021 | Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses the rationale of the TRANSFORM study comparing the safety and efficacy of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) as a second-line treatment in patients with high-risk relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) (NCT03575351). This trial was based on the results of the TRANSCEND-NHL-001 trial (NCT02631044) which led to the approval of liso-cel in the third-line setting. Dr Kamdar explains that the preliminary results of TRANSFORM are promising and could lead to the approval of this chimeric antigen receptor (CAR) T-cell therapy in the second-line setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
